Leadership Changes and Bold Moves Shake Global Drugmakers
In a series of notable announcements, GSK appoints insider Luke Miels as CEO while Emma Walmsley steps down. Kala Bio scraps its lead treatment, sending shares plummeting. Genmab acquires Merus NV for $8 billion, and AstraZeneca announces a full U.S. listing amid concerns of UK exit.
In a surprising turn of events, British pharmaceutical giant GSK has named insider Luke Miels as the successor to CEO Emma Walmsley, who is stepping down after a significant tenure. The move underscores the company's intent to enhance its pipeline amid U.S. trade tariff challenges.
Meanwhile, Kala Bio's stock took a drastic 93% fall in premarket trading following the announcement that its leading drug failed to meet primary study goals. The news underscores the volatile nature of drug development success.
In other industry news, Denmark's Genmab has purchased Merus NV for $8 billion, marking a major acquisition aimed at strengthening its oncology portfolio. Additionally, AstraZeneca has opted for a direct U.S. listing, while confirming its commitment to the UK market.
- READ MORE ON:
- GSK
- Emma Walmsley
- Luke Miels
- Kala Bio
- Genmab
- Merus
- pharmaceuticals
- AstraZeneca
- IPO
- U.S. tariffs
ALSO READ
Trump's Tariff Tsunami: Impact on Indian Cinema & Pharmaceuticals
Germany Awaits U.S. Tariff Decisions on Pharmaceuticals and Trucks
Trump's Tariff Storm: Pharmaceuticals and Trade Wars
Trump's New Tariff Plan Targets Pharmaceuticals, Furniture, and Trucks
Trump's Tariff Storm: Pharmaceuticals, Furniture, and More Face Heavy Duties
Google News